Dive into some
exciting news

SeaStar Medical recognizes that key inflammatory messengers can be transformed. See how we're transforming medicine.

Disruptive thinking from a solutions-oriented organization

SeaStar Medical is a privately held, clinical-stage medical therapeutics company headquartered in Denver, Colorado. Our revolutionary Selective Cytopheretic Device (SCD) is in the final stages of clinical testing with an anticipated launch date in the second half of 2021.

For any media inquiries, please contact psconsulting@seastarmed.com.

Latest News

SeaStar Medical Appoints Kevin Chung, MD as Chief Medical Officer

Dr. Chung is a renowned critical care physician, research and thought leader in extracorporeal life support therapies DENVER, CO and TAMPA, FL, May 24, 2022 — SeaStar Medical Inc., a medical technology company developing a platform therapy to reduce the consequences of hyperinflammation on vital organs, and LMF Acquisition Opportunities, Inc. (NASDAQ: LMAO) (LMAO), a special purpose acquisition company, today announced that Kevin Chung, MD will join SeaStar Medical as Chief Medical Officer (CMO), effective July 1, 2022. Dr. Chung brings over 20 years of experience as an accomplished critical care physician with expertise in extracorporeal life support therapies (ECLS).

Read more >

SeaStar Medical Granted FDA Breakthrough Device Designation for a Novel Immunomodulatory Therapy for Acute Kidney Injury Patients

Designation helps enable accelerated regulatory review of upcoming pivotal clinical trial for treatment in adult patients with acute kidney injury DENVER, CO and TAMPA, FL, May 03, 2022 — SeaStar Medical, a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, and LMF Acquisition Opportunities, Inc. (Nasdaq: LMAO) (“LMAO”), a special purpose acquisition company, today announced that SeaStar Medical’s Selective Cytopheretic Device (SCD) has received a Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). The SCD is a patented, cell-directed, extracorporeal immunomodulator that selectively targets activated neutrophils and monocytes to address hyperinflammation. Neutrophils

Read more >

SeaStar Medical to Become Publicly Listed on Nasdaq via Business Combination with LMF Acquisition Opportunities, Inc.

SeaStar Medical is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs Transaction to provide SeaStar with access to the capital markets, allowing it to accelerate the development and advancement of its proprietary and innovative immunomodulatory platform for pediatric and adult acute kidney injury (AKI) SeaStar Medical plans to advance other programs for acute and chronic inflammations, including conditions associated with Covid-19 Dow Pension Plans, as existing investors of SeaStar Medical, commit to further participate in the transaction through a PIPE investment The proposed business combination is expected to be completed in the third

Read more >

SeaStar Medical Presents Data from SCD 005 Clinical Study at the American Society of Nephrology (ASN) Kidney Week 2021 Annual Meeting

Results show promise for returning a dysregulated immune system to homeostasis in critically ill patients DENVER, CO, November 5, 2021— SeaStar Medical, a medical device company that has redefined how extracorporeal therapies may reduce excessive inflammation on vital organs, announced new data from its SCD 005 clinical study to evaluate the safety and feasibility of the Selective Cytopheretic Device (SCD) in COVID-19 patients with acute kidney injury (AKI) and/or acute respiratory distress syndrome (ARDS). The data were presented at the American Society of Nephrology (ASN) Kidney Week 2021 Annual Meeting. In the poster presentation, “SCD treatment in COVID-19 ICU Patients

Read more >

SeaStar Medical Completes Enrollment of SCD 005 Trial to Evaluate Safety of Selective Cytopheretic Device (SCD) in AKI as well as ARDS Patients with COVID-19

Findings from the study in patients with AKI and/or ARDS with COVID-19 infection are expected later this year DENVER, JUNE 17, 2021 — SeaStar Medical, a medical technology company delivering novel therapeutic solutions to improve organ function, announced today that the company has completed enrollment of the SCD 005 study to evaluate the safety of the Selective Cytopheretic Device (SCD) in patients with acute kidney injury (AKI) and/or acute respiratory distress syndrome (ARDS) with COVID-19 infection. This study builds on previous studies and continues to validate the SCD’s therapeutic approach. Findings are expected later this year. “Completing enrollment of the

Read more >

SeaStar Medical Announces Additions to Board of Directors

— Board members are industry leaders who will actively support company growth strategies — DENVER, Jan. 11, 2021 /PRNewswire/ — SeaStar Medical, a medical technology company delivering novel therapeutic immunomodulating solutions to improve organ function, announced today it has appointed Rick Barnett and Dr. Allan J. Collins to its board of directors, effective January 8, 2021.  “We are excited and honored to welcome Rick and Allan as new independent directors to the SeaStar Medical board, ” said Ray Chow, Chair of the Board of Directors of SeaStar Medical. “They join SeaStar Medical at an important time as we transition to commercializing our Selective Cytopheretic (SCD) therapeutic device. Rick

Read more >

The SCD is an investigational device and is not currently available for sale. Please check back for further updates on device availability in your region.